We are live on ! Find out more
MREO

Mereo BioPharma
MREO

53 hedge funds and large institutions have $84.3M invested in Mereo BioPharma in 2023 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 21 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,668% more call options, than puts

Call options by funds: $775K | Put options by funds: $28K

96% more capital invested

Capital invested by funds: $43M → $84.3M (+$41.3M)

0.59% more ownership

Funds ownership: 9.73% → 10.32% (+0.59%)

9% less funds holding

Funds holding: 58 → 53 (-5)

45% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 11

57% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 21

Holders
53
Holders Change
-5
Holders Change %
-8.62%
% of All Funds
0.83%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
9
Reduced
21
Closed
11
Calls
$775K
Puts
$28K
Net Calls
+$747K
Net Calls Change
+$693K

Top Buyers

Rank Fund Capital Flow
1
MP
Mangrove Partners
Connecticut
+$6.42M
2
BBA
Baker Bros. Advisors
New York
+$4.12M
3
6CM
683 Capital Management
New York
+$3.94M
4
Alkeon Capital Management
Alkeon Capital Management
New York
+$1.57M
5
RCMNY
Rubric Capital Management (New York)
New York
+$1.45M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$5.48M
2
Millennium Management
Millennium Management
New York
-$1.8M
3
Citadel Advisors
Citadel Advisors
Florida
-$1.48M
4
Citigroup
Citigroup
New York
-$799K
5
MAM
Monaco Asset Management
Monaco
-$708K
Name Holding Trade Value Shares
Change 		Change in
Stake
SSA
26
Schonfeld Strategic Advisors
New York
$172K -$34.9K -30,100 -19%
Geode Capital Management
27
Geode Capital Management
Massachusetts
$128K – – –
FA
28
Forefront Analytics
Pennsylvania
$109K -$1.1K -951 -1%
Envestnet Asset Management
29
Envestnet Asset Management
Illinois
$98.6K +$86.7K +74,727 New
HSBC Holdings
30
HSBC Holdings
United Kingdom
$76.8K – – –
CHAM
31
Clear Harbor Asset Management
Connecticut
$74.9K -$27.8K -24,000 -30%
OIA
32
OneDigital Investment Advisors
Kansas
$51.6K +$19.8K +17,100 +78%
PI
33
PFG Investments
New York
$41.6K -$18.6K -16,000 -34%
CC
34
Centiva Capital
New York
$33K – – –
LFAS
35
Level Four Advisory Services
Texas
$26.4K – – –
Jane Street
36
Jane Street
New York
$24.7K -$83.9K -72,347 -79%
GSEP
37
Golden State Equity Partners
California
$19K – – –
OC
38
Oppenheimer & Co
New York
$18.5K -$11.6K -10,000 -42%
NFSG
39
Newbridge Financial Services Group
Florida
$12.5K +$2.9K +2,500 +36%
Morgan Stanley
40
Morgan Stanley
New York
$11.9K – – –
Wells Fargo
41
Wells Fargo
California
$6.9K +$5.8K +5,001 +2,184%
AAP
42
Arax Advisory Partners
Colorado
$5.28K – – –
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$4.3K +$3.78K +3,258 New
UBS Group
44
UBS Group
Switzerland
$3.29K -$109K -93,666 -97%
AF
45
Allworth Financial
California
$1.98K – – –
SIA
46
Sit Investment Associates
Minnesota
$1K – – –
NECFA
47
New England Capital Financial Advisors
Connecticut
$396 – – –
PMFA
48
Plante Moran Financial Advisors
Michigan
$63 – – –
Barclays
49
Barclays
United Kingdom
$50 -$220K -189,969 -100%
US Bancorp
50
US Bancorp
Minnesota
$17 – – –
1
2
3

MREO Hedge Fund Activity: Q2 2023 in Review

53 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q2 2023, worth a combined $84.3M — up 96% from $43M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of MREO and 6 opened new positions — a net loss of 5 holders — while 21 trimmed existing stakes and 9 added.

The largest buyer was Mangrove Partners, opening a new position worth an estimated $6.42M. The largest seller was OrbiMed, exiting entirely with an estimated $5.48M sold.

  • 53 institutional investors held Mereo BioPharma (MREO) as of Q2 2023, down from 58 in Q1 2023.
  • Funds reported $84.3M of Mereo BioPharma stock for Q2 2023, up 96% quarter-over-quarter.
  • 6 funds opened new Mereo BioPharma positions in Q2 2023 and 11 closed out, a net change of -5 holders.
  • The largest Mereo BioPharma buyer in Q2 2023 was Mangrove Partners, an estimated $6.42M added.
  • The largest Mereo BioPharma seller in Q2 2023 was OrbiMed, an estimated $5.48M sold.

Based on aggregated 13F filings for Q2 2023.